Expression of brain‑specific angiogenesis inhibitor‑1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma

Tian,Dawei; Hu,Hailong; Sun,Yan; Tang,Yang; Lei,Mingde; Liu,Liwei; Han,Ruifa; Wu,Changli

doi:10.3892/mmr.2015.3984

Expression of brain‑specific angiogenesis inhibitor‑1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma

Authors:
- Dawei Tian
- Hailong Hu
- Yan Sun
- Yang Tang
- Mingde Lei
- Liwei Liu
- Ruifa Han
- Changli Wu
View Affiliations

Affiliations: Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, P.R. China
Published online on: June 23, 2015 https://doi.org/10.3892/mmr.2015.3984
Pages: 4522-4529

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression levels of brain‑specific angiogenesis inhibitor‑1 (BAI‑1) in bladder transitional cell carcinoma (BTCC) at different stages and the mechanism by which it inhibits tumor endothelial cell proliferation. Normal bladder mucosa biopsy specimens were obtained as the control group, and human BTCC biopsy specimens were used as the study group. Immunohistochemical assays were used to detect the expression levels of BAI‑1, vascular endothelial growth factor (VEGF) and mutant p53, in addition to microvessel density (MVD) in the tissues. Western blotting was used to analyze the differential expression of BAI‑1 in the two samples. Statistical analysis was performed, which indicated that BAI‑1 expression levels in the normal bladder mucosa group were significantly higher than those in the BTCC group and were associated with clinical staging. BAI‑1 levels in the T1 stage BTCC tissues were higher than those in the T2‑4 stage BTCC tissues (P<0.05). BAI‑1 expression levels were negatively correlated with those of VEGF (r=‑0.661, P<0.001), mutant p53 (r=‑0.406, P=0.002) and with the MVD (r=‑0.675, P<0.001). BAI‑1 may be involved in the negative regulation of BTCC microvascular proliferation, and its expression may be associated with a reduction in p53 mutations.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W and Giani G: Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 139:283–285. 1988.PubMed/NCBI
3	Sharifiaghdas F and Beigi FM: Impalpable testis: laparoscopy or inguinal canal exploration? Scand J Urol Nephrol. 42:154–157. 2008. View Article : Google Scholar
4	Reuter VE: The pathology of bladder cancer. Urology. 67(Suppl 1): 11–18. 2006. View Article : Google Scholar : PubMed/NCBI
5	Sylvester RJ, van der Meijden AP and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168:1964–1970. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
7	Davis JW, Sheth SI, Doviak MJ and Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol. 167:494–501. 2002. View Article : Google Scholar : PubMed/NCBI
8	Nam DH, Park K, Suh YL and Kim JH: Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep. 11:863–869. 2004.PubMed/NCBI
9	Yoshida Y, Oshika Y, Fukushima Y, et al: Expression of angiostatic factors in colorectal cancer. Int J Oncol. 15:1221–1225. 1999.PubMed/NCBI
10	Hatanaka H, Oshika Y, Abe Y, et al: Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med. 5:181–183. 2000.PubMed/NCBI
11	Sobin LH and Wittekind C: TNM Classification of Malignant Tumors (UICC). 6th edition. Wiley-Liss; New York, NY: pp. 199–203. 2002
12	Kagan VE, Kisin ER, Kawai K, et al: Toward mechanism-based antioxidant interventions: lessons from natural antioxidants. Ann NY Acad Sci. 959:188–198. 2002. View Article : Google Scholar : PubMed/NCBI
13	Kuwano M, Nakamura Y and Tokino T: A novel brain-specific p53-target gene, BAI1, containing thrombospondin type-1 repeats inhibits experimental angiogenesis. Oncogene. 15:2145–2150. 1997. View Article : Google Scholar
14	Kim E and Deppert W: The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ. 13:885–889. 2006. View Article : Google Scholar : PubMed/NCBI
15	Piaton E, Faÿnel J, Ruffion A, Lopez JG, Perrin P and Devonec M: p53 immunodetection of liquid based processed urinary samples helps to identify bladder tumours with a higher risk of progression. Br J Cancer. 93:242–247. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wei M, Wanibuchi H, Morimura K, et al: Carcinogenicity of dimethylarsinic acid in male F334 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis. 23:1387–1397. 2002. View Article : Google Scholar : PubMed/NCBI
17	Anderson JC, McFarland BC and Gladson CL: New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med. 10:e232008. View Article : Google Scholar : PubMed/NCBI
18	Baenziger NL, Brodie GN and Majerus PW: A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA. 68:240–243. 1971. View Article : Google Scholar : PubMed/NCBI
19	Naumov GN, Bender E, Zurakowski D, et al: A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 98:316–325. 2006. View Article : Google Scholar : PubMed/NCBI
20	Okada K, Hirabayashi K, Imaizumi T, et al: Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomed Res. 31:13–19. 2010. View Article : Google Scholar : PubMed/NCBI
21	Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J and Petrik J: Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol. 210:807–818. 2007. View Article : Google Scholar
22	Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA and Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 138:707–717. 1997. View Article : Google Scholar : PubMed/NCBI
23	Dawson DW, Volpert OV, Pearce SF, et al: Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol. 55:332–338. 1999.PubMed/NCBI
24	Koh JT, Kook H, Kee HJ, et al: Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin. Exp Cell Res. 294:172–184. 2004. View Article : Google Scholar : PubMed/NCBI
25	Nicosia RF: What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol. 153:11–16. 1998. View Article : Google Scholar : PubMed/NCBI
26	Kang SY and Watnick RS: Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal TSP-1 and VEGF expression. APMIS. 116:638–647. 2008. View Article : Google Scholar : PubMed/NCBI
27	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
28	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 41:154–161. 2002.PubMed/NCBI
29	Kato T, Steers G, Campo L, et al: Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Br J Cancer. 97:1277–1286. 2007. View Article : Google Scholar : PubMed/NCBI
30	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
31	El Moustaine D, Granier S, Doumazane E, et al: Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc Natl Acad Sci USA. 109:16342–16347. 2012. View Article : Google Scholar : PubMed/NCBI
32	New DC and Wong YH: Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal. 2:22007. View Article : Google Scholar : PubMed/NCBI